JP2006516112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516112A5 JP2006516112A5 JP2004532124A JP2004532124A JP2006516112A5 JP 2006516112 A5 JP2006516112 A5 JP 2006516112A5 JP 2004532124 A JP2004532124 A JP 2004532124A JP 2004532124 A JP2004532124 A JP 2004532124A JP 2006516112 A5 JP2006516112 A5 JP 2006516112A5
- Authority
- JP
- Japan
- Prior art keywords
- endostatin
- pharmaceutical composition
- individual
- composition according
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102400001047 Endostatin Human genes 0.000 description 14
- 108010079505 Endostatins Proteins 0.000 description 14
- 206010038848 Retinal detachment Diseases 0.000 description 8
- 230000004264 retinal detachment Effects 0.000 description 8
- 201000010183 Papilledema Diseases 0.000 description 7
- 206010038886 Retinal oedema Diseases 0.000 description 7
- 201000011195 retinal edema Diseases 0.000 description 7
- 208000017442 Retinal disease Diseases 0.000 description 6
- 208000001344 Macular Edema Diseases 0.000 description 5
- 206010025415 Macular oedema Diseases 0.000 description 5
- 201000010230 macular retinal edema Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002372 labelling Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40647002P | 2002-08-28 | 2002-08-28 | |
| PCT/EP2003/009497 WO2004020469A2 (en) | 2002-08-28 | 2003-08-27 | Ocular gene therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516112A JP2006516112A (ja) | 2006-06-22 |
| JP2006516112A5 true JP2006516112A5 (enExample) | 2010-06-24 |
| JP4612417B2 JP4612417B2 (ja) | 2011-01-12 |
Family
ID=31978303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004532124A Expired - Fee Related JP4612417B2 (ja) | 2002-08-28 | 2003-08-27 | 眼の遺伝子治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070104684A1 (enExample) |
| EP (1) | EP1534751B1 (enExample) |
| JP (1) | JP4612417B2 (enExample) |
| CN (2) | CN101637611A (enExample) |
| AT (1) | ATE464321T1 (enExample) |
| AU (1) | AU2003258675B2 (enExample) |
| CA (1) | CA2496820A1 (enExample) |
| DE (1) | DE60332122D1 (enExample) |
| IL (1) | IL166950A (enExample) |
| NZ (1) | NZ538958A (enExample) |
| WO (1) | WO2004020469A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100475270C (zh) * | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174861B1 (en) | 1996-10-22 | 2001-01-16 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein |
| JP2001517433A (ja) * | 1997-09-24 | 2001-10-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非霊長類レンチウイルスベクターおよびパッケージングシステム |
| US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
| US6670321B1 (en) * | 1998-12-30 | 2003-12-30 | The Children's Medical Center Corporation | Prevention and treatment for retinal ischemia and edema |
| US6267954B1 (en) * | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
| EP1280929A2 (en) * | 2000-05-01 | 2003-02-05 | Novartis AG | Vectors for ocular transduction and use thereof for genetic therapy |
| WO2001093897A2 (en) * | 2000-06-02 | 2001-12-13 | Entremed, Inc. | Angiostatin and endostatin binding proteins and methods of use |
| AU2002224403A1 (en) * | 2000-10-13 | 2002-04-22 | Entremed, Inc | Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use |
| EP1401480B1 (en) * | 2001-02-22 | 2012-11-28 | Novartis AG | Viral vectors encoding endostatin in the treatment of ocular neovascularization |
| AU2003225544A1 (en) * | 2002-02-04 | 2003-09-02 | Novartis Ag | Recombinant bovine immunodeficiency virus based gene transfer system |
| CA2480809A1 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| WO2004028635A1 (en) * | 2002-09-27 | 2004-04-08 | Novartis Ag | Ocular gene therapy |
-
2003
- 2003-08-27 CN CN200910150526A patent/CN101637611A/zh active Pending
- 2003-08-27 JP JP2004532124A patent/JP4612417B2/ja not_active Expired - Fee Related
- 2003-08-27 US US10/526,127 patent/US20070104684A1/en not_active Abandoned
- 2003-08-27 AT AT03790928T patent/ATE464321T1/de not_active IP Right Cessation
- 2003-08-27 WO PCT/EP2003/009497 patent/WO2004020469A2/en not_active Ceased
- 2003-08-27 DE DE60332122T patent/DE60332122D1/de not_active Expired - Lifetime
- 2003-08-27 CN CNB038231344A patent/CN100526332C/zh not_active Expired - Fee Related
- 2003-08-27 CA CA002496820A patent/CA2496820A1/en not_active Abandoned
- 2003-08-27 EP EP03790928A patent/EP1534751B1/en not_active Expired - Lifetime
- 2003-08-27 NZ NZ538958A patent/NZ538958A/en not_active IP Right Cessation
- 2003-08-27 AU AU2003258675A patent/AU2003258675B2/en not_active Ceased
-
2005
- 2005-02-17 IL IL166950A patent/IL166950A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7503590B2 (ja) | 遺伝子構築物 | |
| JP4361734B2 (ja) | 血管形成の調節に有用なトリプトファニル−ｔＲＮＡシンテターゼ由来ポリペプチド | |
| US10463708B2 (en) | Peptide for treating ocular diseases and composition for treating ocular diseases comprising same | |
| CN102791283A (zh) | 转化生长因子-β1(TGF-β1)抑制剂肽治疗角膜纤维化和/或角膜浑浊的应用 | |
| CN110831960A (zh) | C末端的cdnf和manf片段、包含它们的药物组合物及其用途 | |
| JP7558260B2 (ja) | 眼科障害の処置または防止における使用のための薬剤 | |
| US9127083B2 (en) | Neurturin molecules | |
| WO2002076386A2 (en) | Method of inducing proliferation of retinal stem cells | |
| JP2006516112A5 (enExample) | ||
| US8445432B2 (en) | Neurturin molecules | |
| EP2774935B1 (en) | Improved neurturin molecules | |
| US20140369987A1 (en) | Dermaseptin b2 used as an inhibitor of the growth of a tumor | |
| RU2812055C1 (ru) | Агент для использования при лечении или профилактике офтальмологических расстройств | |
| HK40072504A (en) | Agent for use in treatment or prevention of ophthalmic disorders | |
| CN105017406A (zh) | 一类新的具有神经保护功能的多肽 | |
| HK1252168B (en) | Genetic construct |